Subscribe To
AKBA / Akebia Therapeutics Inc. (AKBA) CEO John Butler on Q2 2022 Results - Earnings Call Transcript
AKBA News
By PennyStocks
August 28, 2023
3 Penny Stocks To Buy According To Analysts, Targets Up To 1,494%
If you're looking to gain an edge in the stock market today, you've got to have more than a list of penny stocks to watch. You need to understand how more_horizontal
By Zacks Investment Research
August 25, 2023
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to more_horizontal
By PRNewsWire
August 23, 2023
Akebia Therapeutics to Report Second Quarter Financial Results and Discuss Recent Business Highlights
Akebia to Host Conference Call on August 25 th at 9:00 a.m. ET CAMBRIDGE, Mass. more_horizontal
By PennyStocks
July 10, 2023
Best Stocks For Beginners with Little Money: How To Trade Penny Stocks
There are so many new traders and investors entering the stock market today. But if you're brand new, you might not have a lot of money to invest or d more_horizontal
By InvestorPlace
July 6, 2023
Pocket Change, Big Gains: 3 Penny Stocks Ready to Boom
Investors seeking high-growth opportunities often turn their attention to penny stocks, which may have the potential to deliver substantial returns. T more_horizontal
By Zacks Investment Research
June 19, 2023
Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?
Here is how Akebia Therapeutics (AKBA) and Haemonetics (HAE) have performed compared to their sector so far this year. more_horizontal
By PennyStocks
June 7, 2023
3 Hot Penny Stocks To Watch Before Next Week
Penny stocks typically trade for less than $5 and generally belong to small companies often overlooked by mainstream investors. Yet, for those willing more_horizontal
By Zacks Investment Research
June 2, 2023
All You Need to Know About Akebia Therapeutics (AKBA) Rating Upgrade to Buy
Akebia Therapeutics (AKBA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (B more_horizontal